IL-13 Signaling in CD30+ Cutaneous Lymphoproliferative Disorders
- 1 May 2021
- journal article
- letter
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (5) , 1360-1363.e3
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (81922058, 81872214)
This publication has 17 references indexed in Scilit:
- SATB1 in Malignant T CellsJournal of Investigative Dermatology, 2018
- SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine ProfileJournal of Investigative Dermatology, 2018
- Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphomaOncotarget, 2016
- Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell LymphomaAesthetic Surgery Journal, 2016
- Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferationBlood, 2015
- CD30+ cutaneous lymphoproliferative disorders with pseudocarcinomatous hyperplasia are associated with a T-helper-17 cytokine profile and infiltrating granulocytesJournal of the American Academy of Dermatology, 2015
- SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21Blood, 2014
- t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5PLOS ONE, 2013
- A novel subset of CD4+ TH2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthmaJournal of Experimental Medicine, 2010
- Hodgkin's Disease, Lymphomatoid Papulosis, and Cutaneous T-Cell Lymphoma Derived from a Common T-Cell CloneNew England Journal of Medicine, 1992